U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
Source: NYT Health - Category: Consumer Health News Authors: Christina Jewett Tags: United States International Relations Drugs (Pharmaceuticals) Factories and Manufacturing United States Politics and Government Biotechnology and Bioengineering Cystic Fibrosis Cancer Supply Chain Intellectual Property Shortages Govern Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | China Health | Cystic Fibrosis | Government | Health | Legislation | Politics | USA Health